SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement

The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.

SCG Cell Therapy (SCG) and the Agency for Science, Technology and Research (A*STAR) have launched joint laboratories to produce novel cell therapies that meet good manufacturing practice (GMP) standards.

With a combined funding of almost $30m, the partnership will focus on induced pluripotent stem cell (iPSC) technology and develop scalable GMP-grade iPSC manufacturing processes and therapeutic candidates.

"The discovery of iPSCs has revolutionised regenerative medicine, offering the potential for standardised, off-the-shelf cell therapies.” Koh Boon Tong, Executive Director, A*STAR's BTI, said.

ALSO READ: NUH to establish health centre for early cancer detection in 2025

The joint laboratories are established at SCG’s GMP facility and A*STAR’s research facility.

Meanwhile, the two organisations also plan to establish a talent development programme to conduct training following current GMP and regulatory requirements.

Follow the link for more news on

healthcare

Also Read

Singaporeans' physical well-being at highest level since 2019

SingHealth partners with OutcomesAI to integrate AI into medical workflows

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

I want to download the media kit